Compare FNGR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNGR | ALLR |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 19.3M |
| IPO Year | 2014 | 2021 |
| Metric | FNGR | ALLR |
|---|---|---|
| Price | $0.18 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.1M | 113.1K |
| Earning Date | 10-27-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,132,261.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.13 | $0.77 |
| 52 Week High | $1.74 | $1.84 |
| Indicator | FNGR | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 26.42 |
| Support Level | $0.15 | $0.78 |
| Resistance Level | $0.37 | $1.45 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 29.12 | 10.59 |
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The Company organizes its operations across four primary areas: telecommunications products and services, marketplace platform and digital commerce infrastructure solutions, data and analytics platform solutions, and Advanced Technology And Platform Solutions. The company generates majority of revenue from telecommunications products and services segment. This segment includes mobile payment and recharge services, as well as enterprise messaging services such as short message services (SMS) and multimedia messaging services (MMS).
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.